settl final humira patent disput lock
exclus boehring agre drop
unclean hand patent thicket argument exchang
launch allow jul royalti sale bi
biosimilar market samsung
total enter
report posit result trial aav-
data show stat sig benefit pt function mobility/
visual acuiti well retin function particular
dose consid pivot vg/ml
commerci opportun indic modest
onc luxturna mediocr sale far potenti
peak sale result showcas mgtx
abil execut central retin deliveri
may result better photoreceptor treatment
compar competitor platform
valid platform ird confid ird
platform valid jnj collabor detail
model updat increas pt op
ad recent collabor
myov liberti readout posit studi
importantli primari came vs
previous flag good rang mid
report sae higher dose vg/kg ignite-dmd
trial cohort transient declin platelet ct elev
alt/bilirubin attribut studi drug attribut
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
still open qn could possibl headwind sentiment
read also use tail wind sentiment
read though howev relat transgen
element uniqu nno bind dom and/or
protocol/ manufactur construct factor
fundament impact srpt/pfe
execut mode readout model
updat chang pt op
on-going screen poc titan chronic
rhinosinus /- nasal polyp underway poc
csu plan move pah
mild/moder
eye competitor nvss
antagonist fevipipr four program
asthma read later year may
myov report result liberti morn studi importantli
primari came
studi met primari endpoint respons rate women receiv daili
oral relugolix combin therapi vs placebo upper end consid
good rang preview note -here
reduct menstrual blood loss baselin import secondari endpoint
easili compar elagolix
importantli compar bone miner densiti receiv
relugolix combin placebo slide call show vs
stock price reaction gaug stock trade fundament balanc bear
thesi win fundament buyer obviou financ overhang bear thesi
around differenti vs elagolix hope respond rate howev
view ultim commerci market uf endometriosi indic driven
small differ respond rate across trial driven total data/clin
profil incl qd/bid add back element current valuation/mkt cap infer modest
sale back envelop sale clearli undemand given multi market
opportun notwithstand slower except ramp elagolix
slide call
sldb dmd program yet identifi dose/protocol express meaning without
sae make micro-dystrophin race seem increasingli like hors race srpt/pfe
dose
dose sgt-
first patient dose safeti issu dose
sever day administr patient hospit due laboratori find includ
decreas platelet count follow
reduct red blood cell count
evid complement activ
patient show sign symptom coagulopathi bleed disord
relev chang baselin liver function test
led clinic hold
clinic hold lift protocol amend light safeti issu first patient
includ addit iv glucocorticoid initi week post administr
enhanc monitor measur includ panel complement activ amend
protocol also specifi eculizumab avail treatment option complement
activ observ
poor microdystrophin express dose sae
microdystrophin detect via wb level quantif assay
fiber via
microdystrophin detect via low level undetect via wb
safeti issu higher dose
shortli dose patient treatment arm diagnos gi infect
classifi seriou advers event unrel studi drug
well transient declin platelet count consid non-seri advers event relat
studi drug event fulli resolv
addit patient experienc transient elev transaminas well transient
increas bilirubin higher time upper limit normal rapidli resolv
increas oral glucocorticoid report fda seriou advers event relat studi drug
safeti issu
base safeti
issu first
express
safeti issu
higher dose
spite amend
question origin safeti issu still unclear relat immunogen high dose data could possibl readthrough also
use relat transgen element uniqu nno bind domain srpt/pfe impact protocol alter steroid
condit potenti resolv issu posit newsflow increasingli fall behind dmd gt race
comparison lead dmd gt program
construct differ exist base preclin data like program potenti demonstr suffici
micro/mini dystrophin express human dose optim given differ promoter/vector capsid key
widespread express
ck reduct improv
muscl strength stamina
multi-year durabl seen golden
retriev yr nhp model
micro-dystrophin
widespread express
force-gen compar wt
detect undetect via wb
express skeletal/cardiac
dmd patient dose vg/kg
fiber micro-dystrophin
reduct ck
improv function nsaa
time rise stair
durabl mo follow
dmd patient dose vg/kg
level micro-dystrophin
express dose
wb biopsi
detect fiber via
dmd pt dose
result undisclos
present
comparison dose across program could meaningless absenc refer standard
signific variabl log could aris base qpcr source/handl pcr reagent
amplicon aav sampl prepar linear vs supercoil supercoil plasmid known
suppress pcr amplif lead log lower dose estim plasmid
evercor isi research clinicaltri gov compani file present press releas nsaa north ambulatori assess sr spectrin-lik repeat domain hing nno
pediatr extens studi initi pivot trial
design discuss fda
complet dose escal adult treat dose
cohort pediatr patient treat extens phase
data longer follow data
treat addit pt extens
cohort safeti efficaci data expect
enrol pt random extens
enrol complet pt adult
dose escal children pediatr
complet dose adult escal dose
cohort pediatr treat extens arm
initi mskcc studi ole data
regulatori author
trial nih on-going initi anoth
multi-cent trial
patient treat first cohort
nih trial initi multi-cent
trial
initi studi
discuss ind late
aim put togeth ind end
acquir vector neurosci parkinson
program updat trial design
fda mid provid regulatori
fda mid provid regulatori
collabor janssen develop riboswitch
technolog vivo preclin data like
enter strateg collabor
janssen gene therapi ird
without np
initi proof concept studi titan
initi proof concept studi
initi trial advanc solid tumor indic
valuat price target deriv dcf termin growth rate line biolog focus smid
cap compani earli product cycl discount rate
risk earli stage clinic compani candid face clinic regulatori commerci risk particular improv result may
seen pediatr earlier treat patient safeti efficaci fall short seen preclin model
valuat price deriv dcf termin growth rate in-line termin growth rate
similar growth compani coverag discount rate reflect clinic natur asset
risk earli stage clinic compani candid face tradit develop regulatori commerci risk nv fevipipr
data binari read-through expect derisk event valu creation point
articl articl
time dissemin may
analyst josh schimmer shenston huang ravi mehrotra regina grebla maneka mirchandaney primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
